Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

481.57 +5.21 (+1.09%)
Streaming Delayed Price Updated: 1:05 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
News headline image
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
Biohaven Stock Earns Relative Strength Rating Upgrade ↗
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today ↗
 
Via Benzinga
News headline image
Navigating 9 Analyst Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings ↗
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
News headline image
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% ↗
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today ↗
 
Via Benzinga
News headline image
Unveiling 6 Analyst Insights On United Therapeutics ↗
 
Via Benzinga
News headline image
Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio? ↗
Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines. 
Via Benzinga
News headline image
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
News headline image
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
United Therapeutics Stock Skids On Mixed Second-Quarter Results ↗
The company's earnings came in far below expectations, though sales easily beat. 
Via Investor's Business Daily
News headline image
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
The 3 Best 3D Bioprinting Stocks to Buy Now ↗
These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector. 
Via InvestorPlace
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Biotech Arvinas Stock Earns 82 RS Rating ↗
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy Now: Q3 Edition ↗
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Undervalued Stocks on Track to Double (or More) by 2028 ↗
The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.